Share Name Share Symbol Market Type Share ISIN Share Description
Evgen Pharma LSE:EVG London Ordinary Share GB00BSVYN304 ORD 0.25P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +0.00p +0.00% 23.50p 22.00p 25.00p 23.50p 23.50p 23.50p 4,578.00 08:00:00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 0.0 -3.2 -6.3 - 17.19

Evgen Pharma Share Discussion Threads

Showing 451 to 475 of 475 messages
Chat Pages: 19  18  17  16  15  14  13  12  11  10  9  8  Older
DateSubjectAuthorDiscuss
06/12/2016
21:19
>>>patvera Likewise, I have quite a bit more invested here too. Evgen have raised a total of just £13m from investors since incorporation and they have enough cash to get them to H1 2018 when they get the initial readout from both the Phase II clinical trials.
timbo003
06/12/2016
19:33
I prefer Evg to ValFully fundedStephen to me is trustworthy and very able
patviera
06/12/2016
08:07
New interview with Stephen Franklin (CEO) from yesterday http://bit.ly/2gxvElH
timbo003
05/12/2016
10:28
There is a new Hardman research report here (which is on my reading list) http://www.directorstalkinterviews.com/wp-content/uploads/2016/11/29.11.16-harnessing-the-clinical-potential-of-sulforaphane.pdf
timbo003
29/11/2016
08:27
As per my post #38, I have started a new thread on Evgen, which I intend to keep topical and up to date unlike this one (and the others) http://uk.advfn.com/cmn/fbb/thread.php3?id=40542081
timbo003
28/11/2016
23:06
I attended the ShareSoc Company Seminar last Wednesday (November 23rd) where Evgen’s CEO Stephen Franklin (SF) gave investors an overview of Evgen and their current clinical program, the presentation lasted around 25 minutes with a further 20 minutes allocated for questions and answers. The slide set used for the presentation can be found here: http://tinyurl.com/zmau5f3 The presentation was not dissimilar to SF’s presentation at the Shares Magazine presentation earlier in the year, which can be accessed here: http://tinyurl.com/h6vk97d After the meeting, I grabbed the opportunity to ask a few additional questions over drinks and canapes. See brief details below along with selected Q&As from the presentation: Q: Slide 12 of the presentation showed Evgens’s 4 main development projects: Metastatic breast cancer, subarachnoid haemorrhage, multiple sclerosis and “other”. How do the analysts value these on a sum of the parts basis? A: They assign roughly equal value and this is based on an NPV basis applying industry standard risk factors to take into account the stage of each project. Q: Are there any readily available analyst research reports on the company? A: The last broker notes valued the company between 79p and 93p/share, there will be a new “paid research” easily accessible note available fairly shortly. Q: Given the low incidence of Ischamic stoke, is there any problem with recruitment and are the recruitment timings on track? A: Yes, it’s on track Q: is the ischemic stroke (IS) study placebo controlled? A: Yes, but both active and placebo groups also receive the current standard of care (SOC) which is a a Calcium channel blocker Q: Presumably for the IS indication the SFX-01 and SOC are administered parenterally as the patient will not be in a state where they can swallow oral dosage forms for some of the time? A: No, both the SFX-01 and the SOC are administered orally through a nasogastric tube when required. This is why it is envisaged that the dosage form is likely to be a capsule which can easily be dispersed in water Q: Is SFX-01 likely to be suitable for all types of cancer? A: In theory yes, SFX-01 has two main mechanisms (see slide 7) both of which are applicable for combating cancer and the mechanism on the RHS of the slide (NF-kB inhibition) is fairly unique and it should suppress cancer stem cells which are responsible for cancer metastasis. SFX-01 has been screen using 400 different cancer cell lines and has shown activity in each case. Q: What could go wrong? A: The greatest risk is that the clinicals fail to produce the desired clinical outcomes. We chose the indications for the two phase II clinicals as they should both give an early read out, whereas if we had opted for an indication such as prostate cancer that would have required many more patients (450 estimate) and taken up to 5 years to complete. Investors and the market require quick results and we have stated that both of the current trials should report in H1/2018, but we hope to over deliver on timings. Q: What about side effects? A: In the phase I dose ranging study we looked at doses up to 700mg and at this level there were a few GI side effects (bloating and Nausea) observed in some patients that were not seen at lower doses, the dose selected for further clinical development was 300mg (twice a day).
timbo003
28/11/2016
22:56
I may use the first few posts for useful info in the future
timbo003
28/11/2016
22:56
I may use the first few posts for useful info in the future
timbo003
28/11/2016
22:56
I may use the first few posts for useful info in the future
timbo003
28/11/2016
22:56
I may use the first few posts for useful info in the future
timbo003
28/11/2016
22:55
It is about time there was a new thread with index and useful content, the other threads contain no useful content and they have been abandoned by their originators having served their purpose and the only thing they attract is tumbleweed
timbo003
28/11/2016
22:51
Evgen Pharma is a clinical stage drug development company focused on cancer and neurological disease, the company began trading in January 2008 and floated on AIM during October 2015 at 37p/share, valuing the company at around £27m. Evgen’s pipeline is based on their proprietary Sulforadex® technology. Sulforadex®, is a means of synthesising and concurrently stabilizing sulforaphane (and synthetic sulforaphane analogues). Sulforaphane is a naturally occurring compound found in broccoli, cabbage and other brassica, although pure sulforaphane is an unstable oily liquid, which needs to be stored at -20C. A significant and growing amount of academic research has demonstrated multiple potential medicinal uses of sulforaphane, however this work has been conducted either with frozen botanical extracts containing unstable sulforaphane, or ambient temperature botanical extracts containing glucoraphanin, the chemical precursor of sulforaphane. Despite the continued academic interest, the inherent unstable nature of sulforaphane has prevented any meaningful progress towards commercial clinical development. Evgen Pharma’s Sulforadex® technology unlocks the medical and commercial potential of sulforaphane (and related novel analogues) by synthesising a stable, solid form, active pharmaceutical ingredient. Lead product, SFX-01, is a patent-protected complex of sulforaphane and alpha-cyclodextrin in a stable powder. It is currently being tested in two proof of concept phase II clinical studies in Ischaemic stroke and in Metastatic breast cancer. Evgen are fully funded up to the beginning of 2018 when both of the phase II proof of concept studies are due to report top line results .     !YOUTUBEVIDEO:PGIoAJ4g2yc: Useful links Evgen web site Aim Admission document (Oct 2015) Annual Report (2016) Sulforophane Wiki page alpha cyclodextrin Wiki page Outline clinical trial protocols on clintrials.gov Review article Neuroprotective Agents in Stroke (Dec 2015) Video of presentation at Shares Mag investor evening (May 19th 2016) Video interview with Evgen CEO on pipeline progress (6th July 2016) Evgen’s Proactiveinvestor page Daily Mail article (25th July 2016)  
timbo003
26/11/2016
01:58
Looking forward to reading it. Thanks
peterm10
23/11/2016
23:04
It was a very useful meeting this evening and I managed to find quite a few new nuggets. I will write up some notes tomorrow and I will post them on a new thread with a proper title and a proper index in the header. This one contains no useful content, the title is fairly meaningless and it appears to be abandoned by its owner (presumably after a quick in and out trade). Evgen deserve better than that.
timbo003
15/11/2016
18:17
Evgen Pharma present at our next London seminar on the 23rd November, more details at: hTTp://www.sharesoc.org/london-nov.html
sharesoc
14/11/2016
21:21
Belated thanks for the link. One of those companies that you just want to work irrespective of shareholding. In for a bit and maybe some more
peterm10
13/11/2016
20:03
He came across well and it looks like a promising company - the only 'but' is a possibility of a fundraising as they have had great feedback on one area (multiple sclerosis) they have not got funds to progress - all the other areas they are fully funded for.
dave444
07/11/2016
21:50
>>>>>peterm I didn't attend the ShareSoc meeting (Leeds is a very long way from Woking), but the slide set is here: http://tinyurl.com/qcbu8s8
timbo003
07/11/2016
21:04
Sharesoc site that is
peterm10
07/11/2016
21:03
Any feedback from the presentation?Couldnt see anything on the shares of site
peterm10
02/11/2016
14:54
Evgen Pharma present at our seminar in Leeds tomorrow, more details and registration available at: hTTp://www.sharesoc.org/leeds-november.html
sharesoc
27/10/2016
12:48
If you would like to meet the company and ask the CEO a few questions then Evgen are presenting at the ShareSoc seminar in Leeds on the 3rd November - here's the link - Http://www.sharesoc.org/leeds-november.html
davidosh
04/10/2016
18:15
I don't really understand why the share price continues to move downwards when there is the possibility of some positive news flow later this year. Perhaps there's en expectation of a placing in the near future?
vatnabrekk
21/9/2016
17:42
OVERBOUGHT SELL ASAP
pumped and dumped
08/9/2016
14:55
Wow more good news evg
patviera
Chat Pages: 19  18  17  16  15  14  13  12  11  10  9  8  Older
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:35 V: D:20161207 22:19:21